figshare
Browse

Data from Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression

Posted on 2023-03-31 - 03:45
Abstract

Cancer develops through the accumulation of genetic and epigenetic aberrations. To identify sequential molecular alterations that occur during the development of hepatocellular carcinoma (HCC), we compared 52 early and 108 overt HCC samples by genome sequencing. Gene mutations in the p53/RB1 pathway, WNT pathway, MLL protein family, SWI/SNF complexes, and AKT/PI3K pathway were common in HCC. In the early phase of all entities, TERT was the most frequently upregulated gene owing to diverse mechanisms. Despite frequent somatic mutations in driver genes, including CTNNB1 and TP53, early HCC was a separate molecular entity from overt HCC, as each had a distinct expression profile. Notably, WNT target genes were not activated in early HCC regardless of CTNNB1 mutation status because β-catenin did not translocate into the nucleus due to the E-cadherin/β-catenin complex at the membrane. Conversely, WNT targets were definitively upregulated in overt HCC, with CTNNB1 mutation associated with downregulation of CDH1 and hypomethylation of CpG islands in target genes. Similarly, cell-cycle genes downstream of the p53/RB pathway were upregulated only in overt HCC, with TP53 or RB1 gene mutations associated with chromosomal deletion of 4q or 16q. HCC was epigenetically distinguished into four subclasses: normal-like methylation, global-hypomethylation (favorable prognosis), stem-like methylation (poor prognosis), and CpG island methylation. These methylation statuses were globally maintained through HCC progression. Collectively, these data show that as HCC progresses, additional molecular events exclusive of driver gene mutations cooperatively contribute to transcriptional activation of downstream targets according to methylation status.

Significance:

In addition to driver gene mutations in the WNT and p53 pathways, further molecular events are required for aberrant transcriptional activation of these pathways as HCC progresses.

CITE THIS COLLECTION

DataCite
No result found
or
Select your citation style and then place your mouse over the citation text to select it.

FUNDING

Japan Agency for Medical Research and Development

SHARE

email

Usage metrics

Cancer Research

AUTHORS (19)

  • Yutaka Midorikawa
    Shogo Yamamoto
    Kenji Tatsuno
    Claire Renard-Guillet
    Shingo Tsuji
    Akimasa Hayashi
    Hiroki Ueda
    Shiro Fukuda
    Takanori Fujita
    Hiroto Katoh
    Shumpei Ishikawa
    Kyle R. Covington
    Chad J. Creighton
    Masahiko Sugitani
    David A. Wheeler
    Tatsuhiro Shibata
    Genta Nagae
    Tadatoshi Takayama
    Hiroyuki Aburatani
need help?